Neuland Laboratories

Neuland Laboratories

NEULANDLAB.NS
Hyderabad, India· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

NEULANDLAB.NS · Stock Price

INR 17,285.00+4856.00 (+39.07%)
Market Cap: $2.4B

Historical price data

Overview

Neuland Laboratories is a mission-driven, pure-play API CDMO that partners with pharmaceutical and biotech companies to accelerate and de-risk the development and manufacturing of complex molecules. The company has achieved significant scale, serving over 500 clients in 80+ countries with a strong regulatory footprint across major global health authorities. Its strategy is centered on deepening its capabilities in high-value niche technologies like peptides, highly potent APIs (HPAPIs), and antibody-drug conjugate (ADC) linkers, while expanding its capacity to capture the growing trend of outsourcing by innovators.

Small MoleculesAntibodiesDrug Delivery

Technology Platform

Proprietary expertise in complex chemical synthesis, process development, and scale-up manufacturing for APIs, with specialized capabilities in peptides, HPAPIs, and ADC linkers/payloads.

Funding History

2
Total raised:$35M
Debt$20M
IPO$15M

Opportunities

The company is poised to capitalize on strong outsourcing trends, especially for complex molecules like peptides and HPAPIs.
Geographic supply chain diversification and the growth of virtual biotechs present significant demand tailwinds.
Its early-engagement model with innovators promises a steady stream of programs transitioning to high-margin commercial supply.

Risk Factors

Key risks include regulatory compliance failures at manufacturing sites, client concentration and project-specific attrition, and pricing pressure in competitive segments.
Geopolitical issues affecting raw material supply and foreign exchange volatility also pose challenges to operational stability and financial performance.

Competitive Landscape

Neuland competes with global CDMOs like Lonza and Catalent, Indian peers like Divi's Laboratories, and cost-aggressive Chinese manufacturers. Its differentiation lies in a pure-play API focus, deep expertise in complex synthesis and niche technologies (peptides, HPAPIs), and a strong regulatory track record, allowing it to command a premium in high-value segments.